AABB Industry Workshop: Dr. Wise Young presents “Cord Blood Therapies as Potential Treatments for People with Chronic Spinal Cord Injury”

Orange County Convention Center, room W224GH | Orlando, FL | Monday, October 24, 2016| 7:00 – 8:15 a.m. eastern time

Industry Workshop: Exclusive Share the Science cellular therapy presentation at the AABB 2016 Annual Meeting

Register for this event to hear Dr. Wise Young, founding director of W. M. Keck Center for Collaborative Neuroscience and Richard H. Shindell Chair in Neuroscience, discuss potential cord blood therapies and clinical applications for people with chronic spinal cord injuries.

To register for the industry workshop, fill out the form on the right. Event is RSVP only. Admission is free but seating is limited. 

Breakfast and attendee check-in will be available beginning at 6:30 a.m. EST in front of the event room.

Attendees who are present will be registered to win an Apple iPad Air.  


Umbilical cord blood (UCB) has long been used to replace bone marrow in patients who have been treated with high-dose chemotherapy for leukemia, hematopoietic diseases, hemoglobinopathy, and other genetic diseases. In the past decade, hundreds of laboratories have reported that UCB cells, particularly UCB mononuclear cells (UCBMNC), have beneficial effects on a variety of conditions, including cerebral palsy, stroke, and spinal cord injury. Several groups have done clinical trials transplanting UCBMNC into the brain and spinal cords of patients, suggesting that the therapies are safe and possibly beneficial. We sought to test the safety and efficacy of UCBMNC transplanted into people with chronic complete spinal cord injury. In addition, because animal studies suggest that lithium stimulates UCBMNC to grow and to produce growth factors that stimulate regeneration, we wanted to assess the effects of a 6-week course of oral lithium carbonate given to patients after transplant of UCBMNC.

After trials to show that patients with chronic complete spinal cord injury can be safely treated with a 6-week course of oral lithium carbonate titrated to serum levels of 0.6-1.2 milliequivalents/liter, we did a phase I trial to transplant 1.6 and 3.2 million UCBMNC into the spinal cord above and below the injury site. This trial involved 8 subjects in Hong Kong. The patients did not receive locomotor training or any special rehabilitation. While some patients recovered several dermatomes of sensation below the injury site, none recovered substantial motor function. We then did a phase II trial in Kunming Army General Hospital (Yunnan Province, China). All patients received three to six months of intensive locomotor training. The promising results of this trial will be described as will plans for upcoming phase IIb trials in China, India, and the US to establish the feasibility of transplanting UCBMNC and training patients with chronic complete spinal cord injury to walk, to confirm the findings from our Kunming trial, and to determine whether lithium is beneficial when combined with UCBMNC transplants.


  • The rationale for using UCBMNC to treat spinal cord injury
  • Why exercise is necessary but not sufficient for recovery
  • How people can recover even after chronic complete spinal cord injury
  • Skepticism of claims that intrathecal administration of UCBMNC will be effective for chronic spinal cord injury, particularly without intensive rehabilitation

Dr. Wise Young, will discuss various clinical applications using UCBMNC to treat spinal cord injury, trial results, and how people can recover from chronic spinal injury.


Wise Young, M.D., Ph.D., Distinguished Professor

Founding Director, W. M. Keck Center for Collaborative Neuroscience

Richard H. Shindell Chair in Neuroscience

Distinguished Professor, Rutgers, The State University of New Jersey

Distinguished Visiting Professor, The University of Hong Kong

Dr. Wise Young, founding director of the W.M. Keck Center for Collaborative Neuroscience and a distinguished professor, is recognized as one of the world’s outstanding neuroscientists.

Dr. Young is committed to bringing treatments to people with spinal cord Injuries. He built and trained a 25-center clinical trial network in China, Taiwan, and Hong Kong, where human clinical trials using umbilical cord blood mononuclear cells and lithium are underway. In the initial results from the phase II trial in Kunming, China, 75% of the participants (15 out of 20) recovered walking with a rolling walker. He is establishing clinical trial networks in the United States, Norway, and India. Phase IIB trials started in 2015, and phase III trials are getting underway this year.

Dr. Young led the team that discovered and established high-dose methylprednisolone (MP) as the first effective therapy for spinal cord injuries. This 1990 work upended concepts that spinal cord injuries were permanent, refocused research, and opened new vistas of hope. He also developed the first standardized rat spinal cord injury model used worldwide for testing therapies, formed the first consortium funded by the National Institutes of Health (NIH) to test promising therapies, and helped establish several widely accepted clinical outcome measures in spinal cord injury research.

Dr. Young founded and served as editor-in-chief of the Journal of Neurotrauma. He organized the International and National Neurotrauma Societies as forums for scientists to collaborate on spinal cord injury and brain research, and he served on advisory committees for the NIH, National Academy of Sciences, NICHD, and on many spinal cord injury advisory boards.

He was awarded a Bachelor of Arts degree from Reed College, a Doctorate from the University of Iowa, and a medical degree from Stanford University. After a surgery internship at New York University and Bellevue Medical Center, he joined the neurosurgery department at NYU, where he became director of neurosurgery research. In 1997, he was recruited to establish a world-class neuroscience research center at Rutgers, The State University of New Jersey.

Dr. Young is in high demand as a speaker at scientific conferences throughout the world and when media are in need of expert knowledge. He has appeared on 20/20 with Barbara Walters and Christopher Reeve, Today Show with Katie Couric, 48 Hours, Fox News, and CNN with Jeff Greenfield. His work was featured in a LIFE magazine special edition, USA Today, and innumerable national and international news and print publications. Some of his many honors include: NIH Jacob Javits Neuroscience Award, Wakeman Award, Tall Texan Award, “Cure” Award, Trustees Award for Excellence in Research, Asian American Achievement Award, Douglass Medal for work with the advancement of young women in the sciences, and Elizabeth M. Boggs Award for service to the disability community. He was the first researcher elected to the Spinal Cord Injury Hall of Fame. Dr. Young received The Hope Award – A Salute to Research Innovation, the New Jersey Educator of the Year Award, the Caring Heart Award, and the Motolinsky Foundation Distinguished Citizen Award. He was also selected as the McGowen Distinguished Lecturer. Recently, BioNJ recognized Dr. Young’s unique contributions by presenting him with its Patient Advocacy Award. In 2006, the Richard H. Shindell Chair in Neuroscience was established at Rutgers University, and Dr. Young was named as the first person to hold that chair. In an issue devoted to cutting edge work in science and medicine, TIME magazine named Dr. Young as “America’s Best” in spinal cord injury research.



An exclusive presentation brought to you by Mediware Information Systems and Save the Cord Foundation.

We look forward to seeing you in Orlando! For questions about registering for this event, contact (913) 307-1015 or grace.godsey@mediware.com